SCHEMBL6791869

SCHEMBL6791869

CC1(C(O)c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)cc2)NC(=O)NC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.44
PHGDH O43175 1/20 0.43
LIPC P11150 1/20 0.43
LIPG Q9Y5X9 1/20 0.43
HRH3 Q9Y5N1 3/20 0.42
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
JAK2 O60674 1/20 0.42
HPGD P15428 3/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TAF1 P21675 1/20 0.41
OTUD7B Q6GQQ9 2/20 0.41
POLB P06746 1/20 0.41
DNMT1 P26358 1/20 0.41
PTPN7 P35236 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6840968 0.90 HPGD (0.47) HSD11B1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL6797530 0.83 PRMT5 (0.39) HRH3ALDH1A1SMN1; SMN2POLBCRBN
SCHEMBL6793526 0.79 CA12 (0.40)
SCHEMBL6791227 0.74 MMP2 (0.41) ALDH1A1MAPT
SCHEMBL6791153 0.74 MMP2 (0.41) ALDH1A1MAPT
SCHEMBL6789361 0.74 MMP2 (0.41) ALDH1A1MAPT
SCHEMBL6798425 0.72 CYP17A1 (0.37) ALDH1A1MAPT
SCHEMBL6840876 0.72 NPC1 (0.45) HSD11B1ALDH1A1KMT2AHPGDSMN1; SMN2
SCHEMBL6791811 0.71 TYR (0.38) POLB
SCHEMBL6792387 0.71 MMP2 (0.45) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 HSD11B1 293/4885PHGDH 1557/4885LIPC 1820/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 HSD11B1 64/4885PHGDH 2636/4885LIPC 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.